---
title: "Erasca | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285988795.md"
datetime: "2026-05-11T20:08:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285988795.md)
  - [en](https://longbridge.com/en/news/285988795.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285988795.md)
---

# Erasca | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.6, missing the estimate of USD -0.2116.

EBIT: As of FY2026 Q1, the actual value is USD -192.36 M.

#### Cash Position and Liquidity

Erasca, Inc. reported cash, cash equivalents, and marketable securities of $408.5 million as of March 31, 2026, an increase from $341.8 million as of December 31, 2025. Working capital was $227,120 thousand as of March 31, 2026, down from $257,728 thousand as of December 31, 2025. Total assets increased to $461,234 thousand as of March 31, 2026, from $396,154 thousand as of December 31, 2025. Total stockholders’ equity was $393,528 thousand as of March 31, 2026, up from $325,171 thousand as of December 31, 2025.

#### Operating Expenses

Research and Development (R&D) expenses were $27.3 million for the quarter ended March 31, 2026, an increase from $26.0 million for the same period in 2025. This increase was primarily due to higher personnel costs, including stock-based compensation, and expenses for clinical trials, preclinical studies, and discovery activities, partially offset by reductions in outsourced services, consulting fees, and facilities-related expenses. Erasca, Inc. also recorded $150.0 million in in-process R&D expense during the quarter ended March 31, 2026, related to the exercise of an option to expand its territory to worldwide under the ERAS-0015 license agreement. General and Administrative (G&A) expenses were $10.6 million for the quarter ended March 31, 2026, up from $9.7 million for the same period in 2025, mainly driven by personnel costs, including stock-based compensation expense. Total operating expenses for the quarter ended March 31, 2026, were $187,911 thousand, significantly higher than $35,630 thousand for the quarter ended March 31, 2025.

#### Profitability

Loss from operations was -$187,911 thousand for the quarter ended March 31, 2026, compared to -$35,630 thousand for the same period in 2025. Net loss for the quarter ended March 31, 2026, was -$183.4 million, compared to a net loss of -$31.0 million for the quarter ended March 31, 2025. The accumulated deficit was -$1,075,649 thousand as of March 31, 2026, compared to -$892,209 thousand as of December 31, 2025.

#### Other Financial Metrics

Interest income was $4,449 thousand for the quarter ended March 31, 2026, compared to $4,740 thousand for the same period in 2025. Other income (expense), net, was $22 thousand for the quarter ended March 31, 2026, versus -$76 thousand for the prior year period. Total other income (expense), net, was $4,471 thousand for the quarter ended March 31, 2026, compared to $4,664 thousand for the quarter ended March 31, 2025. The unrealized loss on marketable securities, net, was -$1,327 thousand for the quarter ended March 31, 2026, compared to a gain of $223 thousand for the quarter ended March 31, 2025. Comprehensive loss was -$184,767 thousand for the quarter ended March 31, 2026, compared to -$30,743 thousand for the same period in 2025.

#### Outlook / Guidance

Erasca, Inc. expects its cash, cash equivalents, and marketable securities to fund operations into the second half of 2028. The company anticipates releasing ERAS-0015 monotherapy expansion and combination dose escalation data in the first half of 2027. Preliminary Phase 1 monotherapy data for ERAS-4001 are expected in the second half of 2026, with the initiation of monotherapy expansion and combination dose escalation cohorts planned for 2027.

### Related Stocks

- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Autohome Inc. to Announce First Quarter 2026 Financial Results on May 28, 2026 | ATHM Stock News](https://longbridge.com/en/news/286390966.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)